For research use only. Not for therapeutic Use.
Tegobuvir (CAT: I000067) is an investigational antiviral drug that belongs to the class of non-nucleoside inhibitors of the hepatitis C virus (HCV) NS5B polymerase. It is being studied for the treatment of chronic HCV infection. Tegobuvir works by inhibiting the replication of the HCV RNA genome, thereby suppressing viral replication. It has demonstrated potent antiviral activity against various genotypes of HCV in preclinical and clinical studies. Tegobuvir is often used in combination with other direct-acting antiviral agents as part of an interferon-free regimen for the treatment of HCV infection. Clinical trials have shown promising results, and further research is ongoing to evaluate its efficacy and safety.
| Catalog Number | I000067 |
| CAS Number | 1000787-75-6 |
| Synonyms | 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine |
| Molecular Formula | C25H14F7N5 |
| Purity | ≥95% |
| Target | HCV Protease |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| Overview of Clinical Research | <span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Tegobuvir is a hepatitis C virus NS 5 protein inhibitor.</span></span></span> |
| IUPAC Name | 5-[[6-[2,4-bis(trifluoromethyl)phenyl]pyridazin-3-yl]methyl]-2-(2-fluorophenyl)imidazo[4,5-c]pyridine |
| InChI | InChI=1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2 |
| InChIKey | XBEQSQDCBSKCHJ-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C(=C1)C2=NC3=CN(C=CC3=N2)CC4=NN=C(C=C4)C5=C(C=C(C=C5)C(F)(F)F)C(F)(F)F)F |
| Reference | <br /> |
